UBS analyst Kevin Caliendo raised the firm’s price target on Envista (NVST) to $25 from $22 and keeps a Neutral rating on the shares. Envista shows strong fundamentals driven by solid year-to-date execution, positive management tone, and improving utilization trends, with potential margin upside from Spark improvements and stabilizing equipment sales extending beyond 2025, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVST:
- Envista price target raised to $21 from $19 at Piper Sandler
- Jefferies EU medical tech analyst holds analyst/industry conference call
- Envista upgraded to Neutral from Underperform at Mizuho
- Envista price target raised to $22 from $20 at JPMorgan
- Envista ‘sounded upbeat’ regarding dental market, says Stifel